Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veliparib - Abbvie

Next Previous
Drug Profile

Veliparib - Abbvie

Alternative Names: ABT-888; NSC-737664

Latest Information Update: 20 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie
  • Class Amides; Antineoplastics; Benzimidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Breast cancer; Colorectal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours; Testicular cancer
  • Phase I/II Glioma; Head and neck cancer; Prostate cancer; Small cell lung cancer
  • Phase I Leukaemia
  • No development reported Lymphoma; Multiple myeloma
  • Discontinued Liver cancer

Most Recent Events

  • 28 May 2025 Pharmacokinetics data from preclinical trial presented at the 126th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2025)
  • 21 Mar 2025 National Cancer Institute completes a phase II trial in Breast cancer and Triple-negative breast cancer (Combination therapy, Second-line therapy or greater) in Puerto Rico and USA (PO, Capsule) (NCT02595905)
  • 05 Apr 2024 Efficacy data from the phase II I-SPY trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top